Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on December 11, 2020. The Company is a Nevada corporation with principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The NASDAQ Stock Market LLC under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a regulatory compliance event rather than financial performance results.
Material Changes
The primary material event reported is the resolution of a listing compliance issue. On October 29, 2020, the Company received notification from Nasdaq regarding non-compliance with the minimum bid price requirement under Listing Rule 5550(a)(2). On December 11, 2020, Nasdaq notified the Company that it has regained compliance. This was achieved because the closing bid price of the Company's common stock was at least $1.00 per share for 10 consecutive business days from November 27, 2020, through December 10, 2020. The matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or new risks. The document confirms the removal of the specific risk associated with potential delisting due to the minimum bid price requirement.
Key Facts for Investor Verification
- The Company has successfully regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The compliance was met by maintaining a closing bid price of $1.00 or greater for 10 consecutive trading days ending December 10, 2020.
- The delisting risk associated with the minimum bid price requirement has been resolved as of December 11, 2020.
- No financial data or operational updates are included in this specific filing.